Clinical trial
Hydralazine and Valproate Added to Chemotherapy for Breast Cancer
NCT00395655 · National Institute of Cancerología, Other · Terminated
Key facts
| NCT number | NCT00395655 |
|---|---|
| Title | Hydralazine and Valproate Added to Chemotherapy for Breast Cancer |
| Official title | A Phase II Clinical Study of Hydralazine and Valproic Acid in Combination With Neoadjuvant Cytotoxic Chemotherapy in Stage IIB and IIIA Breast Carcinoma |
| Lead sponsor | National Institute of Cancerología, Other |
| Collaborators | National Council of Science and Technology, Mexico Psicofarma, S.A. De C.V. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Locally Advanced Breast Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Hydralazine and magnesium valproate administration, Core-needle biopsy of the breast |
| Enrollment | 43 |
| Start date | Jun 1, 2005 |
| Completion | Aug 1, 2006 |
| First posted | Nov 3, 2006 |
| Last update posted | Nov 3, 2006 |
| Countries | Mexico |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: